Edding Group Company Limited

Our company

Our company

Core Therapeutic Areas

Our therapy areas

Full Value Chain

Full Value Chain

Career

Career

简繁

Corporate News

EDDING ANNOUNCES NMPA APPROVAL OF VASCEPA® (Icosapent Ethyl) FOR NEW CARDIOVASCULAR RISK REDUCTION（CVRR）INDICATION IN MAINLAND CHINA

2024-07-05

NMPA Accepts Marketing Application for VASCEPA® (icosapent ethyl) Cardiovascular Risk Reduction (CVRR) Indication
2023-11-15
EDDING RECEIVES REGULATORY APPROVAL FOR MULPLETA® (Lusutrombopag Tablets) in MAINLAND CHINA
2023-06-29
EDDING RECEIVES REGULATORY APPROVAL FOR VASCEPA® (Icosapent Ethyl) IN MAINLAND CHINA
2023-06-01
EDDING Receives Approval of VASCEPA® to Reduce Cardiovascular Risk in Hong Kong,China
2022-03-29

Lusutrombopag Phase III Study Results in Mainland China was published on Hepatology International

EDDING announced that the applications for drug approval of lusutrombopag have been officially accepted in Mainland China

Edding Shares Topline Data —— Pivotal Phase III Study of Lusutrombopag in Mainland China

EDDING announced that the applications for drug approval of VASCEPA® have been officially accepted in Mainland China

Edding Shares Topline Data —— Pivotal Phase III Study of VASCEPA® in Mainland China

Eddingpharm's subsidiary Suzhou Ceclor Pharmaceutical Co., Ltd. is officially unveiled

Shionogi Concludes Licensing Agreements with Eddingpharm for Lusutrombopag, a Thrombopoietin Receptor Agonist

U.S. FDA Grants Priority Review for Vascepa® (Icosapent Ethyl) Supplemental New Drug Application Seeking Cardiovascular Risk Reduction Indication

Eddingpharm Get Two Legacy Antibiotics Brands and Manufacturing Facility in China

Eddingpharm announces an exclusive agreement with Roche China for the promotion and distribution of Recormon® in China

Eddingpharm announces an exclusive agreement with Lilly China for the promotion and distribution of Ceclor® and Vancocin® in China

Amarin and Eddingpharm Announce Agreement to Develop and Commercialize Vascepa® (icosapent ethyl) in China

Media Center

2019-11-13

活动回顾

ag真人游戏平台医药收英文

Media Center

Company Overview

Download

Media kit

Download

Unit 122-129, Building A3, No. 700, Wanrong Road， Shanghai，China

pr@jsdongyue.com

沪ICP备65169002号

Copyright © 2019 ag真人游戏平台医药版权所有

药监局备案号: (沪) -非经营性-2021-0038

ag真人游戏平台